Skip to main content
. 2023 Jan 25;24(3):147–161. doi: 10.1007/s11864-023-01051-w

Fig. 1.

Fig. 1

Schema of upcoming NRG-HN012 trial to compare RT with concurrent and adjuvant xevinapant, a second mitochondria-derived activator of caspases (SMAC) mimetic, vs. RT with concurrent cetuximab in patients with locally advanced head and neck cancer who have a contraindication to cisplatin.